Hypertension and the metabolic syndrome

Diabetologia Croatica

Volumn 37, Issue 4, 2008, Pages 83-89

  Duvnjak, Lea ^a   Bulum, Tomislav ^a   Metelko, Željko ^a  

^a University of Zagreb   (Croatia)

Author keywords

Hypertension; Insulin resistance; Metabolic syndrome; Visceral obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLINE DERIVATIVE; INSULIN; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SODIUM; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANTHROPOMETRY; ATHEROGENESIS; BLOOD VESSEL INJURY; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; KIDNEY DYSFUNCTION; KIDNEY INJURY; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; SODIUM RETENTION; SUBCUTANEOUS TISSUE; WEIGHT REDUCTION;

EID: 58149502144     PISSN: 03510042     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Guidelines Committee. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-1187.
2. Kearney PM, Whelton M, Reynolds K, Mountner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223.
3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-1576.
4. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995;18:181-196.
5. Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The sixth report (JNC VI). Arch Intern Med 1997;157:2413-2446.
6. Chobanian AV, Bakris GL, Black HR, ET AL. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. J Hypertens 2003;42:1206-1252.
7. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
8. Kjeldsen Sverre E, Naditch-Brule L, Perlini, S. Zidek W, Farsang Csaba E. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with Hypertension Disease survey. J Hypertens 2008;26:2064-2070.
9. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: WHO, 1999.
10. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2468-2497.
11. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
12. Kahn R, Ferrannini E. Buse J, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28:2289-2304.
13. Alberti KGMM, Zimmet PZ. Should we dump the metabolic syndrome? No. BMJ 2008;336:641-646.
14. Khan SH, Khan FA, Ijaz A, Sattar A, Dilwar M, Hashim R. Hypertension and metabolic syndrome: impact of clustering of hypertension in subjects with metabolic syndrome. Pak Med Sci 2007;23:903-908.
15. Franklin SS. Hypertension in the metabolic syndrome. Vol. IV: Metabolic syndrome and related disorders. Irvine: Mary Ann Liebert, Inc.. 2005:287-298.
16. Reaven GM. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: syndrome X revisited. In: Jefferson LS, Cherrington AD, eds. Handbook of physiology. Section 7: The endocrine system. Vol. II: The endocrine pancreas and regulation of metabolism. New York, NY: Oxford University Press, 2001:1169-1197.
17. Reaven GM. Insulin resistance and its consequences. In: LeRoith D, Taylor SI, Olefasky JM, eds. Diabetes mellitus: a fundamental and clinical text. 3rd ed. Philadelphia: Lippincott. Williams and Wilkins, 2004: pp. 899-915.
18. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004;20:295-304.
19. Flakoll PJ, Jensen MD, Cherrington AD. Physiological action of insulin. In: LeRoith D. Taylor SI, Olefasky JM, eds. Diabetes mellitus: a fundamental and clinical text. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins, 2004: pp. 165-181.
20. Low Wang C, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovacsular biology. Diabetes 2004;53:2735-2740.
21. Sowers JR, Fronlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004;88:63-82.
22. Despres JP. Health consequences of visceral adiposity. Ann Med 2001:33.534-541.
23. Rahmouni K, Correia MLG, Haynes WG. Mark AL. Obesity-associated hypertension - new insights into mechanisms. Hypertension 2005;45:9-14.
24. Rupp H. Maisch B. Abdominal fat and sympathetic overactivity. Herz 2003;28:668-673.
25. Sanjuliani AF, DeAbreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006;60:621-629.
26. Grassi G, Van Zwieten PA. Sympathetic nervous system and renin-angiotensin system interactions. J Hypertens 2001;19:1713-1716.
27. Schachter M. Blood pressure reduction in the metabolic syndrome and type 2 diabetes. Br J Diabetes Vasc Dis 2005,5:320-324.
28. Bakris GL. Current perspectives on hypertension and metabolic syndrome. J Manag Care Pharm 2007;13:S3-S5.
29. Abuissa H, Jones PG, Marson SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-826.
30. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005;42:S17-S25.
31. Bousquet P. II receptors, cardiovascular function, and metabolism. Am J Hypertens 2001;14:317-321.
32. Schillaci G, Pirro M, Vaudo G, ET AL. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004;43:1817-1822.